Chroma secures new investment of 135M for Series B in genetic medicines
Biospace - 01-Mar-2023Epigenetic medicine approach avoids the pitfalls of traditional CRISPR method of gene editing
Join the club for FREE to access the whole archive and other member benefits.
Life Sciences Writer at BioSpace
Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she's never looked back. She's been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer's disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing.
Passionate writer currently focused on the life sciences industry. Looking to broaden base of connections on LinkedIn, particularly in the biopharma world, for future articles and expert opinions.
Visit website: https://www.biospace.com/staticpages/10284/contributors/
See alsoDetails last updated 05-Mar-2023
Epigenetic medicine approach avoids the pitfalls of traditional CRISPR method of gene editing